IDEX (IEX) Q1 FY26 earnings call

IDEX delivered a strong Q1 FY26, exceeding expectations with 5% organic sales growth and 10% organic order growth, primarily driven by its Health & Science Technologies segment. The company raised its full-year organic growth outlook to 3-4%, reflecting confidence from a growing backlog in advantaged markets like data center and space & defense. While some short-cycle industrial businesses showed mixed improvement, the company maintains a balanced capital deployment strategy, including share repurchases and active M&A.